INMD Stock Recent News
INMD LATEST HEADLINES
InMode's Q1 2025 results disappointed, with revenue and EPS missing estimates, leading to a 12% stock drop and another potential guidance cut. Despite solid fundamentals and attractive valuation, weakening demand, no buybacks, and uncertain forecasts make me downgrade INMD from Buy to Hold. The company has high margins, lots of cash, and operates in a growing market, but short-term catalysts are lacking.
InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects.
New York, New York--(Newsfile Corp. - April 28, 2025) - Eyes On Park, a leading optometry practice in Gramercy Park, announces the introduction of the cutting-edge Envision by InMode system for comprehensive dry eye treatment. Dr. Irina Shiyan and her team now offer this advanced, non-invasive technology that combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, not just the symptoms.
InMode Ltd. (NASDAQ:INMD ) Q1 2025 Earnings Conference Call April 28, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - CEO Yair Malca - CFO Conference Call Participants Matt Miksic - Barclays Danielle Antalffy - UBS Matt Taylor - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Sam Eiber - BTIG Dane Reinhardt - Baird Operator Good day, and welcome to InMode's First Quarter 2025 Earnings Results Conference Call.
InMode (INMD) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.45 per share a year ago.
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025.
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels.
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.